AU2001266289A1 - 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury - Google Patents

2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury

Info

Publication number
AU2001266289A1
AU2001266289A1 AU2001266289A AU6628901A AU2001266289A1 AU 2001266289 A1 AU2001266289 A1 AU 2001266289A1 AU 2001266289 A AU2001266289 A AU 2001266289A AU 6628901 A AU6628901 A AU 6628901A AU 2001266289 A1 AU2001266289 A1 AU 2001266289A1
Authority
AU
Australia
Prior art keywords
head injury
closed head
arachidonylglycerol
inhibitor
necrosis factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266289A
Inventor
Aviva Breuer
Ruth Gallily
Raphael Mechoulam
David Panikashvili
Esther Shohami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2001266289A1 publication Critical patent/AU2001266289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to 2-arachidonylglycerol (2-AG) to be used as inhibitor of a tumor necrosis factor (TNF-alpha), in the reduction of edema caused by closed head injury, in the reduction of neurological deficits caused by closed head injury and stroke and in treating pathological conditions caused by TNF-alpha and/or by radical oxygen intermediates (ROI), in pharmaceutical composition for the same use comprising as active ingredient 2-AG. It comprises also the use of 2-AG and pharmaceutical compositions comprising same in the preparation of a medicament for the treatment of said indications and methods of treatment by 2-AG and pharmaceutical compositions comprising same for diseases caused by said indications.
AU2001266289A 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury Abandoned AU2001266289A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21370500P 2000-06-23 2000-06-23
US60/213,705 2000-06-23
PCT/IL2001/000551 WO2001097793A2 (en) 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury

Publications (1)

Publication Number Publication Date
AU2001266289A1 true AU2001266289A1 (en) 2002-01-02

Family

ID=22796176

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266289A Abandoned AU2001266289A1 (en) 2000-06-23 2001-06-17 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury

Country Status (8)

Country Link
US (1) US6566543B2 (en)
EP (1) EP1292288B1 (en)
JP (1) JP2003535892A (en)
AT (1) ATE277608T1 (en)
AU (1) AU2001266289A1 (en)
DE (1) DE60106026T2 (en)
ES (1) ES2227220T3 (en)
WO (1) WO2001097793A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314103B2 (en) * 2001-05-25 2007-07-12 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
JP2003048831A (en) * 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
EP1509250B1 (en) 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
JP2007502805A (en) 2003-08-18 2007-02-15 ビーティージー・インターナショナル・リミテッド Treatment of neurodegenerative conditions
GB0319358D0 (en) * 2003-08-18 2003-09-17 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
JP2006083136A (en) * 2004-09-17 2006-03-30 Suntory Ltd Composition having action for preventing or ameliorating lowering of cerebral function caused by stress and symptom or disease involving the same lowering
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
CN101631542B (en) 2006-12-28 2011-12-21 三得利控股株式会社 Nerve regeneration agent
JP2010540618A (en) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド Endogenous cannabinoids to increase infant growth and development
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20200069618A1 (en) * 2018-09-04 2020-03-05 John C. Gustin Compositions having an agent and an enhancer thereof, methods of use, and delivery systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247165B (en) * 1991-03-15 1994-12-12 Fidia Spa THERAPEUTIC USE OF PHOSPHATIDYLSERINE AND DERIVATIVES IN DEGENERATIVE PATHOLOGIES, ALSO ASSOCIATED WITH IMMUNITARY DYSFUNCTIONS.
US5456912A (en) * 1993-12-28 1995-10-10 The Regents Of The University Of California Non-methylene interrupted fatty acids as immunomodulators
CA2326766A1 (en) * 1998-04-03 1999-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusale M Synthetic endogenous cannabinoids analogues and uses thereof

Also Published As

Publication number Publication date
EP1292288A2 (en) 2003-03-19
JP2003535892A (en) 2003-12-02
ES2227220T3 (en) 2005-04-01
WO2001097793A3 (en) 2003-01-09
US6566543B2 (en) 2003-05-20
ATE277608T1 (en) 2004-10-15
WO2001097793A2 (en) 2001-12-27
US20020072539A1 (en) 2002-06-13
DE60106026D1 (en) 2004-11-04
DE60106026T2 (en) 2006-02-23
EP1292288B1 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
WO2004004661A3 (en) Boroproline compound combination therapy
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
ATE506059T1 (en) THERAPY TO TREAT OVERACTIVE BLADDER
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
DE60331537D1 (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
MXPA04004966A (en) 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
PL371428A1 (en) Substituted indolizine-like compounds and methods of use
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2002089794A8 (en) Method for treating neuropathic pain and pharmaceutical preparation therefor
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
DE60135904D1 (en) DRUGS FOR THE TREATMENT OF NERVE DISEASES
EP2292226A3 (en) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof